stockrow
Saturday 7 November 2026
Export AKTS’s income statement to Excel — free account
Aktis Oncology, Inc.
AKTS Healthcare Biotechnology
Aktis Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.5 million, up 336.9% from fiscal 2024.
15.78
0.93
+6.26%
Follow AKTS
Alert me
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+3 more TTM periods Free account |
— | — | — | (34.45%) | |
| — | 0.00% | 0.00% | (22.22%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
— | 0.00% | 0.00% | (14.86%) | |
Average Days of Receivables |
— | — | — | 0.00 | |
Free Cash Flow per Share |
(72.96) | 0.00 | (2.82) | (2.52) | |
Free Cash Flow |
(58.90) | (98.90) | (136.90) | (139.37) | |
Capital Expenditures |
(10.00) | (15.87) | (14.87) | (14.23) | |
| Other line items | |||||
Cash ROIC |
0.00% | (23.89%) | (13.11%) | (13.91%) | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Accounts Payable Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 826.24% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 212.89% | |
Share Based Compensation of Revenue |
— | — | — | 93.15% | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 1.66 | |
Depreciation/Fixed assets |
0.00 | (0.48) | (0.28) | (0.19) | |
Capex/Depreciation |
1.50 | 2.29 | 3.45 | 4.61 | |
Revenue per Share |
0.00 | — | 0.00 | 0.17 | |
Operating CF per Share |
(60.58) | 0.00 | (2.51) | (2.26) | |
Capex per Share |
(12.38) | 0.00 | (0.31) | (0.26) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 1.47 |
Columns are period end dates · fundamentals updated 26 Oct 2026